#1 Clinical Trials Search in Europe

Dexamethasone Ph. Eur.

Dexamethasone, a potent corticosteroid, is being extensively studied in clinical trials for the treatment of multiple myeloma. These trials aim to evaluate its effectiveness when used in combination with other drugs to improve outcomes for patients with newly diagnosed, relapsed, or refractory multiple myeloma. The studies explore various drug combinations and treatment strategies to find the most effective approaches for managing this challenging blood cancer.

Table of Contents

What is Dexamethasone?

Dexamethasone is a powerful corticosteroid medication that plays a crucial role in the treatment of multiple myeloma, a type of blood cancer that affects plasma cells[1]. It is known by various names, including DEXAMETHASONE PH. EUR. and is available in tablet form for oral use[1].

How Dexamethasone is Used in Multiple Myeloma Treatment

Dexamethasone is widely used in the treatment of multiple myeloma due to its anti-inflammatory and immunosuppressive properties. It helps in several ways:

  • Reducing inflammation in the body
  • Suppressing the immune system to slow down the growth of cancer cells
  • Alleviating symptoms associated with multiple myeloma, such as bone pain and fatigue
  • Enhancing the effectiveness of other anti-myeloma drugs when used in combination therapies

Combination Therapies Including Dexamethasone

Dexamethasone is often used in combination with other medications to treat multiple myeloma. Some common combination therapies include:

  • VRd: Bortezomib (Velcade), Lenalidomide (Revlimid), and Dexamethasone[2]
  • DRd: Daratumumab, Lenalidomide, and Dexamethasone[2]
  • DPd: Daratumumab, Pomalidomide, and Dexamethasone[3]
  • EPd: Elotuzumab, Pomalidomide, and Dexamethasone[1]
  • PVd: Pomalidomide, Bortezomib, and Dexamethasone[1]

These combinations are used in various stages of multiple myeloma treatment, including newly diagnosed cases, relapsed or refractory disease, and as maintenance therapy[2].

Dosage and Administration

The dosage of dexamethasone can vary depending on the specific treatment regimen and the patient’s individual needs. In the clinical trials reviewed, the following information was noted:

  • Dexamethasone is typically administered orally in tablet form[1]
  • The maximum daily dose can be up to 40 mg[3]
  • Treatment duration can vary, with some regimens lasting up to 172 weeks (approximately 3.3 years)[3]

It’s important to note that the exact dosage and schedule should be determined by your healthcare provider based on your specific condition and treatment plan.

Potential Side Effects

While dexamethasone is an effective treatment for multiple myeloma, it can cause side effects. Some potential side effects include:

  • Increased risk of infections
  • Changes in blood sugar levels
  • Mood changes or irritability
  • Insomnia
  • Increased appetite and weight gain
  • Fluid retention
  • Osteoporosis (with long-term use)
  • Muscle weakness

It’s crucial to discuss any side effects you experience with your healthcare provider, as they may be able to adjust your treatment or provide ways to manage these effects[2].

Precautions and Considerations

When taking dexamethasone, there are several important precautions and considerations to keep in mind:

  • Inform your doctor about any allergies or hypersensitivities you may have to dexamethasone or its components[1]
  • Dexamethasone may interact with other medications, so it’s important to inform your healthcare provider about all medications you’re taking
  • Long-term use of dexamethasone may suppress your immune system, increasing your risk of infections
  • If you’re pregnant, planning to become pregnant, or breastfeeding, discuss the risks and benefits of dexamethasone with your doctor
  • Do not stop taking dexamethasone abruptly without consulting your healthcare provider, as this can lead to withdrawal symptoms

Dexamethasone is a powerful medication that plays a crucial role in the treatment of multiple myeloma. While it can be highly effective, it’s important to use it under close medical supervision and to communicate openly with your healthcare team about any concerns or side effects you may experience.

Aspect Details
Drug Name Dexamethasone Ph. Eur.
Formulation Tablet, 2.0mg
Main Indications Multiple Myeloma (newly diagnosed, relapsed, or refractory)
Common Combinations VRd, DPd, DVd, Rd, PVd, Kd
Trial Phases Phase 2 and Phase 3
Primary Endpoints Progression-Free Survival, Minimal Residual Disease negative rate
Patient Populations Newly diagnosed, transplant-ineligible, relapsed/refractory after 1-4 prior lines of therapy
Administration Route Oral use
Max Daily Dose 40mg (in some trials)
Treatment Duration Varies by trial, from months to years

FAQ

  • What is dexamethasone and how is it used in multiple myeloma treatment? Dexamethasone is a powerful corticosteroid medication. In multiple myeloma treatment, it is often used in combination with other drugs to reduce inflammation, suppress the immune system, and help kill cancer cells. It can be given orally or intravenously as part of various treatment regimens.
  • What are some common drug combinations that include dexamethasone in these trials? Common combinations include VRd (bortezomib, lenalidomide, and dexamethasone), DPd (daratumumab, pomalidomide, and dexamethasone), and DVd (daratumumab, bortezomib, and dexamethasone). These combinations are being studied to determine their effectiveness in treating multiple myeloma at different stages.
  • What is the purpose of using dexamethasone in combination with other drugs? Dexamethasone is used in combination with other drugs to enhance their effectiveness. It can help reduce side effects from other treatments, decrease inflammation, and directly contribute to killing myeloma cells. The combination approach often leads to better outcomes than using single drugs alone.
  • Are there any specific side effects associated with dexamethasone use in these trials? While specific side effects are not detailed in the trial summaries, common side effects of dexamethasone can include increased appetite, weight gain, mood changes, difficulty sleeping, and increased risk of infections. The trials closely monitor patients for any adverse effects.
  • How long do patients typically receive dexamethasone treatment in these trials? The duration of dexamethasone treatment varies depending on the specific trial and treatment regimen. In some studies, it may be given for several months, while in others, it could be part of a longer-term maintenance therapy. The exact duration is determined by the study protocol and individual patient response.

Ongoing Clinical Trials on Dexamethasone Ph. Eur.

  • Study Comparing Belantamab Mafodotin with Lenalidomide and Dexamethasone to Daratumumab with Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Greece +5

  • Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

    Recruiting

    2 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

  • Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

    Recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8

  • Study on the Effects of Oseltamivir and Drug Combination for Patients with Pneumonia

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Estonia France Italy The Netherlands Portugal +3

  • Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Greece Italy +3

  • Efficacy and Safety Evaluation of Belantamab Mafodotin Versus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Belgium Bulgaria France Germany Greece Hungary +4

  • Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +7

  • Study of JNJ-68284528 for Treating Multiple Myeloma in Patients Using Ciltacabtagene Autoleucel and Drug Combination

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Belgium France Germany The Netherlands Spain

  • Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Denmark France Germany Greece Italy +4

  • Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +10

Glossary

  • Multiple Myeloma: A type of blood cancer that affects plasma cells, which are a type of white blood cell that normally produces antibodies to fight infections.
  • Relapsed Multiple Myeloma: Multiple myeloma that has returned after a period of improvement following treatment.
  • Refractory Multiple Myeloma: Multiple myeloma that does not respond to treatment or stops responding after initial improvement.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it getting worse.
  • IMWG Criteria: International Myeloma Working Group criteria, which are standardized guidelines used to diagnose multiple myeloma and assess treatment response.
  • Minimal Residual Disease (MRD): A small number of cancer cells that remain in the body during or after treatment.
  • Autologous Stem Cell Transplant (ASCT): A procedure where a patient's own stem cells are collected, stored, and then returned to them after high-dose chemotherapy to help restore the bone marrow.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Used in cancer treatment and diagnosis.
  • Proteasome Inhibitor (PI): A type of drug that blocks the action of proteasomes, which are cellular complexes that break down proteins. PIs can help kill cancer cells.
  • Immunomodulatory Drug (IMiD): A type of drug that modifies the immune system's response. In multiple myeloma treatment, IMiDs can help enhance the immune system's ability to fight cancer cells.

References

  1. http://clinicaltrials.eu/trial/study-comparing-talquetamab-pomalidomide-and-teclistamab-for-patients-with-relapsed-or-refractory-myeloma-after-1-to-4-prior-treatments/
  2. http://clinicaltrials.eu/trial/study-comparing-bortezomib-lenalidomide-and-dexamethasone-with-ciltacabtagene-autoleucel-for-newly-diagnosed-multiple-myeloma-patients-not-planning-stem-cell-transplant/
  3. http://clinicaltrials.eu/trial/study-comparing-talquetamab-daratumumab-and-pomalidomide-with-drug-combination-for-patients-with-relapsed-or-refractory-multiple-myeloma/